Lipella Pharmaceuticals Inc. 8-K Report: Key Updates and Insights
Based on the provided section of the financial report, here are the key insights extracted:
- Entity Information:
- Company Name: Lipella Pharmaceuticals Inc.
- CIK (Central Index Key): 0001347242
- SEC File Number: 005-93847
- EIN (Employer Identification Number): 20-2388040
- Address: 7800 Susquehanna St. Suite 505, Pittsburgh, PA 15208
- Contact Number: (412) 894-1853
- Filing Type:
- Filing Form: 8-K
- Filing Date: February 24, 2025
- Stock Information:
- Common Stock: Par value of $0.0001 per share
- Ticker Symbol: LIPO
- Exchange: NASDAQ
- Context Information:
- Reporting Date: As of February 24, 2025
- Measurement Units:
- Currency: USD
- Shares: Measured in shares
- Per Share Value: USD per share
Summary Insights:
- The report pertains to Lipella Pharmaceuticals Inc., which is publicly traded on NASDAQ under the ticker LIPO.
- The filing is an 8-K, typically used to report unscheduled material events or corporate changes.
- The report provides essential company identification details and indicates a common stock structure with a very low par value, which may suggest a strategy to maintain flexibility in equity financing or stock options.
This information would be relevant for investors, analysts, and stakeholders interested in the company's current status and reporting activities.